Pinneberg/Munich, Germany – 30.10.2023 – The international expansion of terraplasma medical GmbH, a subsidiary of the Viromed Group, is progressing. The strategic mainstay is the innovative treatment of wounds based on cold atmospheric plasma (KAP). The focus is on the mobile, CE-certified cold plasma device plasma care®, which closes wounds painlessly and inactivates viruses, fungi and bacteria. Terraplasma medical, which emerged from the Max Planck Institute, developed the device and holds the patents.
With the CE certification in 2019, the medical device approval in the EU has been achieved. After the initial start in Germany, the market launch was successfully carried out in other European countries over the past year. Thus, in Italy, the BENELUX countries and especially Switzerland as important markets, sales cooperations with significant purchase quantities could be entered into. The same applies to several Eastern European markets such as Poland, Romania, Slovenia and Hungary. For next year, the next country cooperations are already in the pipeline with Portugal, Slovakia and Serbia. In the European markets, the initial focus is on wound care, often in the area of post-operative wound healing disorders, but also chronic wounds.
Strengthening the market position in the field of cold plasma technology
Since the beginning of 2023, successful sales partnerships have been established in the Middle East. For example, a leading medical technology company has been acquired for Saudi Arabia, the United Arab Emirates and Bahrain. In addition, initial sales partnerships have been established in Turkey and Jordan. Here, there are very different requirements for approval as a medical device. In some markets, such as Turkey, this is based on CE certification in Europe, while in others, such as Saudi Arabia, a demanding approval by the health authorities is required, which is expected in the first half of 2024. In a very fast growing and emerging market environment, plasma care® is highly regarded and in demand as an innovative German product.
A distribution agreement in Brazil with a leading company in wound care was concluded as early as 2022. Following a strict and detailed approval process by the Brazilian health authority (ANVISA), plasma care® has now been approved for the Brazilian market. This underscores the high safety and effectiveness standards of the device. As a result, the device was presented and sold in detail to the attending physicians at the trade fair stand and in lectures at the most important Brazilian conference for plastic surgery (SIITTRAL) in October. In the South American market, the initial focus is on plastic surgery and postoperative wound healing disorders.
In addition, plasma care® was approved in Venezuela as a further Latin American market and presented at the national surgical congress.
Approval and market launch in the first Asian markets is expected in early 2024. Taiwan and South Korea also offer an ideal market environment for innovative high-tech products made in Germany. Contracts have already been concluded with two national medical technology companies for substantial purchase volumes in the multi-million range. Agreements have also been reached with Japanese and Chinese companies for a joint market entry in the near future.
“The interest in our German cold plasma technology is huge,” says Jens Kirsch, Managing Director of terraplasma medical GmbH.
“Depending on the country, the topics of wound care, dermatology, and the beauty and aesthetics segment are at the top of the list. While Brazil and Venezuela clearly focus on beauty topics, countries like Italy and Holland tend to concentrate on wound care.”Jens Kirsch
“The use of novel cold plasma technology in medical technology will replace conventional treatment methods and reduce the use of antibiotics and cortisone,” says Professor Dr. Gregor Morfill, renowned cold plasma expert and Chairman of the Supervisory Board of Viromed Medical AG. “Among other things, this concerns postoperative wound healing disorders, chronic wounds and dermatological skin diseases. For this reason, the Viromed Group had acquired a majority stake in terraplasma medical in August last year.” The aim, he said, was to strengthen the company’s market position in the field of cold plasma technology and, in addition to the existing distribution rights for wound treatment in the DACH region, to gain direct access to the underlying IP (intellectual property), patents and technologies, as well as global marketing in all indication areas of terraplasma medical GmbH.
About Viromed Medical AG
Hamburg-based Viromed Medical AG is part of the Viromed Group, which has been active in the healthcare market since 2004 with a focus on protection against viruses and germs. The wholly owned subsidiary Viromed Medical GmbH is at the heart of the stock corporation, which has been listed on the stock exchange since October 2022. Its strategic mainstay is the innovative treatment of wound healing based on cold atmospheric plasma (KAP). The focus is on the mobile, CE-certified cold plasma device plasma care®, which closes wounds painlessly and inactivates viruses, fungi and bacteria. The technical developer and patent holder of the cold plasma technology is terraplasma medical GmbH in Garching near Munich, which emerged from the Max Planck Institute. To ensure long-term access to the technology, a sister company from the Viromed Group acquired a majority stake in terraplasma medical GmbH in August 2022. The use of plasma care® represents a quantum leap for wound healing. In addition, further medical applications are possible in the fields of cosmetics as well as dermatology and ENT.
Viromed Medical AG has a broad customer base in the DACH region, including various DAX companies, e.g. Volkswagen and Lufthansa, as well as federal states and various federal ministries, 1,100 hospitals, 7,000 pharmacies and 11,000 medical practices. www.viromed-medical-ag.de
Petra Rulsch PR – Strategic Communication +